Category : Search result: MSME pharma

CII Mangaluru Hosts MSME Conclave on Scaling, Leadership & Innovation

CII Mangaluru MSME Conclave: Powering Growth

CII Mangaluru's MSME Conclave at Hotel Vivanta focuses on scaling SMEs via leadership, capital & innovation. Industry leaders to discuss digital adoption & global competitiveness.

Aurobindo Pharma to Boost Stake in Chinese JV to 50%, Eyes Full Control by 2029

Aurobindo Pharma increases stake in China JV to 50%

Aurobindo Pharma's Dutch arm buys 20% more in China's Luoxin Aurovitas for $5M, aiming for 100% ownership by 2029 to scale up inhalation product manufacturing. Read the full strategic move.

Indian Pharma's 2026 Pivot: A 5-Year Race to $500B & Innovation Hub Status

India Pharma Targets $500B, Innovation Hub by 2047

India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.

Orissa HC Slams Bank's 4% Foreclosure Fee, Calls Mobility a Right

Orissa HC Quashes 4% Foreclosure Fee on MSME Loan

Orissa High Court rules banks cannot charge for loan foreclosure, protecting MSME rights. Landmark verdict orders document release, waives unfair fee. Read the full judgment details.

MCCIA Helpline Guides 2,500+ MSMEs Across Maharashtra in One Year

MCCIA Helpline Aids 2,500+ MSMEs in Maharashtra

MCCIA's dedicated helpline has transformed MSME support in Maharashtra, guiding over 2,500 businesses across 35 districts. Discover how this initiative and new AI studio are empowering small enterprises.

Sudeep Pharma IPO Lists Today: 20% Gains Expected After 93x Subscription

Sudeep Pharma IPO Lists on BSE, NSE Today

Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.

2 Indian Firms to Profit from Semaglutide Pen Boom in 2026

Indian Companies Set for Semaglutide Device Windfall

Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.

Sudeep Pharma IPO Allotment Today After 93.71 Times Subscription

Sudeep Pharma IPO Allotment Status Today

Sudeep Pharma IPO allotment finalized today after massive 93.71x subscription. GMP at ₹87 signals 14.67% listing gain. Track your allotment status now!

Sudeep Pharma IPO Subscribed 94x as Institutional Demand Soars

Sudeep Pharma IPO Subscribed 94 Times

Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.

Greenex & Norway's EPD Global Partner to Boost Indian EPD Access by 70%

India-Norway Pact Cuts EPD Certification Cost by 70%

Pune's Greenex partners with Norway's EPD Global to help Indian manufacturers, especially MSMEs, get Environmental Product Declarations. This strategic move cuts certification costs and boosts global market competitiveness.

MSME Bank Loans Plummet 88% in PMEGP Scheme as Lenders Turn Cautious

MSME loans shrink 88% in flagship govt scheme

Bank lending to first-time micro-entrepreneurs under PMEGP drops sharply due to rising NPAs, US tariffs, and tighter credit norms. Only 12,707 projects supported this fiscal year.

Lupin at 21x P/E: Undervalued Pharma Giant Ready for Growth Cycle?

Lupin: Undervalued Pharma Giant at 21x P/E?

Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.

Page 1 of 4